April 12, 2024 06:56 AM EDT
Deals
China

I-Mab CEO de­tails con­sid­er­a­tions be­hind Chi­na split, hints at po­ten­tial in-li­cens­ing

Amber Tong

I-Mab’s CEO is hop­ing its re­cent re­or­ga­ni­za­tion — split­ting its US and Chi­na op­er­a­tions — will sim­pli­fy its in­vest­ment the­sis by shift­ing the risk …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times